Company intelligence / Profile preview

MVP Laboratories

Omaha, Nebraska, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

MVP Laboratories was a developer and manufacturer of animal vaccines and specialized adjuvant systems, with commercial products and global distribution, including herd-specific (autogenous) vaccine solutions and robust diagnostic services for farm clients. In January 2016, MVP was acquired by Phibro Animal Health Corporation, which continues to market adjuvant technologies under the MVP Technologies brand.

Therapeutic areas: Infectious Diseases
Modalities: VaccineVaccine adjuvantDiagnostic (lab services for farms)
Industry: Veterinary

Partnerships

MJ Biologics, Inc. (distribution agreement for MJPRRS® autogenous swine vaccine)

Beyond the preview

Go deeper on MVP Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP Laboratories.

Explore the full profile